-66.6%
RBLX vs GSK
+31.2%
-97.9%
-74.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | -1.9% | +6.3% | +4.0% |
| 7D | +12.4% | -1.8% | +14.2% | +12.1% |
| 30D | +19.7% | -2.2% | +21.8% | +19.3% |
| 3M | -0.1% | -1.8% | +1.7% | -0.2% |
| 6M | -35.7% | -10.6% | -25.1% | -37.6% |
| YTD | -46.6% | +4.4% | -51.0% | -45.4% |
| 1Y | -66.6% | +30.4% | -97.0% | -65.3% |
| All | -66.6% | +31.2% | -97.9% | -65.3% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling